Sign in
VRCA Stock Price, Chart, Stats & News
Verrica Pharmaceuticals Inc.
Save
62.31M
Market cap
–
Current P/E
–
Forward P/E
VRCA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 90.80% |
Operating margin | -33.56% |
Pretax margin | -50.27% |
Net margin | -50.27% |
Effective tax rate | – |
ROA | -37.95% |
ROE | 252.30% |
D/E | 0.07x |
Interest coverage ratio | -1.54x |
VRCA valuation
P/E | – |
P/S | 1.31x |
P/B | 1.89x |
P/CF | -2.65x |
P/FCF | -2.65x |
P/OCF | -2.65x |
PEG | -0.05x |
EV multiple | -6.74x |
About
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications.
Similar securities
Based on sector and market capitalization
Report issue